Jason Cohen, Editor

About the Author Jason Cohen, Editor


Catalyst Pharmaceuticals (CPRX): A Biotech Stock This Analyst Is Closely Watching

Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …

Theravance’s (TBPH) COPD Drug Wins FDA Approval

Today, the FDA approved Theravance’s (TBPH) Yupelri (revefenacin) inhalation solution for the treatment of COPD. Thervance and Mylan (MYL) are partnered on the opportunity.

What to Do with Omeros (OMER) Stock Following 20% Sell-Off?

Did an iceberg just wallop into Omeros (OMER) stock? The drug maker’s shares are plunging at breakneck speed of almost 20%.

AcelRx (ACRX) Tumbles After Stock Offering Prices at Deep Discount

Shares of biotechnology company AcelRx (ACRX) are tumbling – down nearly 17% as of this writing. The reason?

Catalyst Pharmaceuticals (CPRX): We Are Confident of Firdapse’s Approvability, Says Analyst

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expecting the FDA to rule on its marketing application for Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert …

Advanced Micro Devices (AMD) Stock Divides Analysts After Next Horizon Conference

Advanced Micro Devices (AMD) shares rose nearly 4% yesterday after the chip giant’s Next Horizon event kicked off with the announcement that the first …

Here’s Why This Analyst Boosted Price Target for Amarin (AMRN) Stock

Amarin (AMRN) investors should expect material news on November 10, as that’s when the fish oil drug maker plans to release additional details from …

J.P. Morgan Pours Cold Water on Puma Biotechnology (PBYI) Stock

Investors weren’t impressed with Puma Biotechnology (PBYI) latest earnings report, and at least one Wall Street analyst has had enough. J.

Cantor Pounds the Table on Amarin (AMRN) Stock

Cantor analyst Louise Chen was out pounding the table on shares of Amarin (AMRN) Thursday, reiterating an Overweight rating with a price target of $35, which …

Last Minute Thought: Buy or Sell Advanced Micro Devices (AMD) Stock Before 3Q18 Earnings?

OK, Advanced Micro Devices (AMD). It’s officially earnings season again, and time to show investors what you’re made of.